Listen
Reason for request
Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).
-
Clinical Benefit
| Substantial |
The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication. |
Clinical Added Value
| important |
SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS. |
English version
Contact Us
Évaluation des médicaments
